Literature DB >> 6328323

Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells.

H M Friedman, G H Cohen, R J Eisenberg, C A Seidel, D B Cines.   

Abstract

Receptors for the Fc portion of immunoglobulins or for the third component of complement (C3) are present on a variety of circulating and fixed tissue cells including granulocytes, monocytes, lymphocytes and glomerular epithelial cells. Cells which lack Fc receptors may express them after infection by herpes simplex virus (HSV)-1, HSV-2, cytomegalovirus or varicella zoster virus. We recently reported that infection by HSV-1 induces both Fc and C3 receptors on human endothelial cells. Glycoprotein E of HSV-1 has been shown to function as an Fc receptor. We now demonstrate that glycoprotein C (gC) of HSV-1 functions as a C3b receptor. This receptor appears following HSV-1, but not HSV-2, infection. Detection of the C3b receptor is blocked by monoclonal antibodies to glycoprotein C (gC) of HSV-1, but not by monoclonal antibodies to other HSV-1 glycoproteins. In addition, the MP mutant of HSV-1, which lacks gC, fails to express a C3b receptor. These results assign a new function of gC of HSV-1 and demonstrate potentially important differences between HSV-1 and HSV-2 glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328323     DOI: 10.1038/309633a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  168 in total

1.  Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease.

Authors:  C E Saldanha; J Lubinski; C Martin; T Nagashunmugam; L Wang; H van Der Keyl; R Tal-Singer; H M Friedman
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  Type I interferons and herpes simplex virus infection: a naked DNA approach as a therapeutic option?

Authors:  S Noisakran; D J Carr
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Interferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway.

Authors:  Daniel J J Carr; Khaldun Al-khatib; Cassandra M James; Robert Silverman
Journal:  J Neuroimmunol       Date:  2003-08       Impact factor: 3.478

5.  Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells.

Authors:  K E Van Vliet; L A De Graaf-Miltenburg; J Verhoef; J A Van Strijp
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

6.  New member of the multigene family of complement control proteins in herpesvirus saimiri.

Authors:  J C Albrecht; B Fleckenstein
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

7.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

8.  Attachment of human polymorphonuclear leukocytes to herpes simplex virus-infected fibroblasts mediated by antibody-independent complement activation.

Authors:  J A van Strijp; K P van Kessel; L A Miltenburg; A C Fluit; J Verhoef
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

9.  A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G.

Authors:  I Frank; H M Friedman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  Mouse monoclonal antibodies specific for endothelial cells.

Authors:  F Drenk; U Sander; U Alheid; A Serbin; H Deicher
Journal:  Mol Cell Biochem       Date:  1987-07       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.